First Postpartum Depression Drug Approved by FDA Postpartum depression can be devastating for new moms. It affects 1 in 9 women. Now, a drug has finally been approved to treat it. The FDA has approved intravenous infusions of brexanolone, which will be marketed as Zulresso. The treatment requires a <br />60-hour IV drip. Mild side effects such as headache, dizziness <br />and excessive sleepiness may occur. But the drug, available in June, may have barriers for some women. Sage Therapeutics confirmed that the drug could be priced around $20,000 to $35,000 per treatment. Dr. Tiffany Farchione, FDA Division of Psychiatry Products
